DE60103927D1 - Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems - Google Patents
Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystemsInfo
- Publication number
- DE60103927D1 DE60103927D1 DE60103927T DE60103927T DE60103927D1 DE 60103927 D1 DE60103927 D1 DE 60103927D1 DE 60103927 T DE60103927 T DE 60103927T DE 60103927 T DE60103927 T DE 60103927T DE 60103927 D1 DE60103927 D1 DE 60103927D1
- Authority
- DE
- Germany
- Prior art keywords
- production
- ventilation system
- treating disorders
- piperazine derivatives
- central ventilation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25330100P | 2000-11-28 | 2000-11-28 | |
US253301P | 2000-11-28 | ||
US29781401P | 2001-06-13 | 2001-06-13 | |
US297814P | 2001-06-13 | ||
PCT/US2001/043160 WO2002044142A2 (en) | 2000-11-28 | 2001-11-27 | Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60103927D1 true DE60103927D1 (de) | 2004-07-22 |
DE60103927T2 DE60103927T2 (de) | 2005-06-23 |
Family
ID=26943115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60103927T Expired - Lifetime DE60103927T2 (de) | 2000-11-28 | 2001-11-27 | Piperazinderivate, deren Herstellung und deren Verwendung in der Behandlung von Störungen des Zentralnervensystems |
Country Status (25)
Country | Link |
---|---|
US (3) | US6469007B2 (de) |
EP (1) | EP1339406B1 (de) |
JP (1) | JP4198989B2 (de) |
KR (1) | KR100835552B1 (de) |
CN (1) | CN100352437C (de) |
AR (1) | AR035603A1 (de) |
AT (1) | ATE269078T1 (de) |
AU (2) | AU3765402A (de) |
BR (1) | BR0115609A (de) |
CA (1) | CA2428039C (de) |
DE (1) | DE60103927T2 (de) |
DK (1) | DK1339406T3 (de) |
EA (1) | EA005925B1 (de) |
ES (1) | ES2222401T3 (de) |
HK (1) | HK1057864A1 (de) |
HU (1) | HUP0400551A2 (de) |
IL (1) | IL156098A0 (de) |
MX (1) | MXPA03004677A (de) |
NO (1) | NO325501B1 (de) |
NZ (1) | NZ526150A (de) |
PL (1) | PL363219A1 (de) |
PT (1) | PT1339406E (de) |
TR (1) | TR200401546T4 (de) |
TW (1) | TWI224102B (de) |
WO (1) | WO2002044142A2 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432826B1 (en) * | 1999-11-29 | 2002-08-13 | Applied Materials, Inc. | Planarized Cu cleaning for reduced defects |
US20060287335A1 (en) * | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
US20060223824A1 (en) * | 2000-11-28 | 2006-10-05 | Wyeth | Serotonergic agents |
WO2003007956A1 (en) * | 2001-07-20 | 2003-01-30 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
US7361773B2 (en) | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
JP2005527530A (ja) | 2002-03-12 | 2005-09-15 | ワイス | キラル1,4−二置換ピペラジン |
US7091349B2 (en) | 2002-03-12 | 2006-08-15 | Wyeth | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
AU2003220094B2 (en) | 2002-03-12 | 2009-04-23 | Wyeth, A Corporation Of The State Of Delaware | Process for synthesizing chiral N-aryl piperazines |
GB0219961D0 (en) * | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
WO2004082686A2 (en) * | 2003-03-13 | 2004-09-30 | Dynogen Pharmaceuticals, Inc. | Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
US20070099931A1 (en) * | 2004-03-19 | 2007-05-03 | Wyeth | Pharmaceutical dosage forms and compositions |
US20050209245A1 (en) * | 2004-03-19 | 2005-09-22 | Wyeth | Process for preparing N-aryl-piperazine derivatives |
KR100646337B1 (ko) * | 2004-06-30 | 2006-11-23 | 주식회사 롯데기공 | 보일러의 누수 감지방법 |
AU2005295640B2 (en) | 2004-10-15 | 2011-07-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multi-domain amphipathic helical peptides and methods of their use |
TW200700413A (en) * | 2005-03-01 | 2007-01-01 | Wyeth Corp | Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
CA2612109A1 (en) * | 2005-06-17 | 2006-12-28 | Wyeth | Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists |
WO2007089616A2 (en) * | 2006-01-26 | 2007-08-09 | The University Of Rochester | Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier |
TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
AR063984A1 (es) * | 2006-11-28 | 2009-03-04 | Wyeth Corp | Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado |
CL2008000119A1 (es) | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
US8936787B2 (en) * | 2008-04-15 | 2015-01-20 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Peptides promoting lipid efflux |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU645681B2 (en) | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
GB9514901D0 (en) | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
-
2001
- 2001-11-13 US US10/010,575 patent/US6469007B2/en not_active Expired - Fee Related
- 2001-11-27 AR ARP010105502A patent/AR035603A1/es not_active Application Discontinuation
- 2001-11-27 HU HU0400551A patent/HUP0400551A2/hu unknown
- 2001-11-27 TR TR2004/01546T patent/TR200401546T4/xx unknown
- 2001-11-27 BR BR0115609-8A patent/BR0115609A/pt not_active Application Discontinuation
- 2001-11-27 AU AU3765402A patent/AU3765402A/xx active Pending
- 2001-11-27 NZ NZ526150A patent/NZ526150A/en unknown
- 2001-11-27 MX MXPA03004677A patent/MXPA03004677A/es active IP Right Grant
- 2001-11-27 IL IL15609801A patent/IL156098A0/xx unknown
- 2001-11-27 DE DE60103927T patent/DE60103927T2/de not_active Expired - Lifetime
- 2001-11-27 CA CA2428039A patent/CA2428039C/en not_active Expired - Fee Related
- 2001-11-27 PT PT01986458T patent/PT1339406E/pt unknown
- 2001-11-27 ES ES01986458T patent/ES2222401T3/es not_active Expired - Lifetime
- 2001-11-27 JP JP2002546512A patent/JP4198989B2/ja not_active Expired - Fee Related
- 2001-11-27 DK DK01986458T patent/DK1339406T3/da active
- 2001-11-27 PL PL01363219A patent/PL363219A1/xx not_active Application Discontinuation
- 2001-11-27 AT AT01986458T patent/ATE269078T1/de not_active IP Right Cessation
- 2001-11-27 CN CNB018196853A patent/CN100352437C/zh not_active Expired - Fee Related
- 2001-11-27 KR KR1020037007064A patent/KR100835552B1/ko not_active IP Right Cessation
- 2001-11-27 EP EP01986458A patent/EP1339406B1/de not_active Expired - Lifetime
- 2001-11-27 EA EA200300619A patent/EA005925B1/ru not_active IP Right Cessation
- 2001-11-27 TW TW090129285A patent/TWI224102B/zh not_active IP Right Cessation
- 2001-11-27 AU AU2002237654A patent/AU2002237654B2/en not_active Ceased
- 2001-11-27 WO PCT/US2001/043160 patent/WO2002044142A2/en active IP Right Grant
-
2002
- 2002-08-14 US US10/218,251 patent/US6586436B2/en not_active Expired - Fee Related
-
2003
- 2003-05-20 US US10/441,536 patent/US7026320B2/en not_active Expired - Fee Related
- 2003-05-27 NO NO20032390A patent/NO325501B1/no not_active IP Right Cessation
-
2004
- 2004-02-04 HK HK04100730A patent/HK1057864A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60103927D1 (de) | Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems | |
DE602004015269D1 (de) | Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten. | |
ATE294171T1 (de) | Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung | |
DE60233265D1 (de) | 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten | |
ATE447561T1 (de) | Substituierte aryl 1,4-pyrazin derivate | |
DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
DE60136736D1 (de) | Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose | |
ATE420097T1 (de) | Substituierte sapogenine und ihre verwendung | |
ATE420866T1 (de) | 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
NO20014303D0 (no) | JAK-3-inhibitorer for behandling av allergiske lidelser | |
ATE296634T1 (de) | (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
DE60023012D1 (de) | 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel | |
DE69901177D1 (de) | Platinkomplex, dessen herstellung und dessen therapeutische verwendung | |
ATE332294T1 (de) | Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung | |
ATE261972T1 (de) | 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde | |
DE10084441T1 (de) | Koalinton-Pigmente, ihre Herstellung und Verwendung | |
EE200200442A (et) | Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks | |
ATE384699T1 (de) | 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten | |
DE69833297D1 (de) | Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS) | |
DE69523654D1 (de) | Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen | |
NO20031903L (no) | Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser | |
DE60009155D1 (de) | Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung | |
DE59510604D1 (de) | UV-Absorber, ihre Herstellung und Verwendung | |
ATE251170T1 (de) | Titanverbindungen, deren herstellung und verwendung | |
ATE303379T1 (de) | 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |